StocksMedium•5 November 2026•
1 min read
Siemens Healthineers Initiates Diagnostics Carve-Out as Olyrian Diagnostics
Key Facts
1Siemens Healthineers has initiated the carve-out process for its in vitro diagnostics business to establish it as a standalone company.
2The new brand name, Olyrian Diagnostics, will be rolled out in stages as part of the standalone organization setup.
Siemens Healthineers has initiated the carve-out process for its in vitro diagnostics business to establish it as a standalone company. GlobeNewswire reported that the new brand name, Olyrian Diagnostics, will be rolled out in stages as part of the transition to an independent organization.
SMMNY closed at $25.32 on November 4, 2026, after reaching a day high of $25.32 and a low of $24.96. The rebranding and formal carve-out are intended to prepare the diagnostics business to operate independently, potentially facilitating future strategic maneuvers for the entity.